Brief: Alzinova Reports Positive Results From Phase 1B Extension Part Of Alz-101 Study
09/12/2024 06:31
Dec 9 (Reuters) - Alzinova AB ALZ.ST :
* ALZINOVA REPORTS POSITIVE RESULTS FROM THE PHASE 1B
EXTENSION
PART OF THE ALZ-101 STUDY IN ALZHEIMER'S DISEASE
* IMMUNE RESPONSE FROM VACCINATION WITH ALZ-101 IS ROBUST
AND
LONG-LASTING IN MORE THAN 95% OF PATIENTS
* ALZ-101 STUDY: EXPLORATORY ENDPOINTS REGARDING IMPACT OF
TREATMENT ON COGNITIVE AND FUNCTIONAL PARAMETERS HAVE BEEN
ANALYZED WITH RESULTS SHOWING A POSITIVE DOSE-DEPENDENT TREND
Source text: ID:nMFN5lvdrz
Further company coverage: ALZ.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))